Evogene Ltd. — Form SCHEDULE 13D/A
Filed August 13, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 18/100
What the filing says
This is an amended Schedule 13D/A filing dated August 13, 2026, relating to Evogene Ltd. (Israeli agricultural biotech firm, SIC 2870). The filer is identified as an entity/individual associated with addresses in Herzelia Pituah and Rehovot, Israel. The filing document itself contains no substantive disclosure of ownership percentages, share counts, transaction amounts, or material changes to previously reported beneficial ownership positions—only administrative and entity identification information is visible in this filing header.
Why this rating
Routine amendment to ownership disclosure; no material transaction, stake change, or economic substance disclosed in text provided.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.